SCHEMBL19338069

SCHEMBL19338069

CCN1CCN(c2ccc(Nc3cc(N(C)C)ncn3)cc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LCK P06239 8/20 0.60
▸ FGFR3 P22607 5/20 0.60
▸ FGFR4 P22455 4/20 0.60
▸ ALK Q9UM73 3/20 0.60
▸ FGFR1 P11362 3/20 0.60
▸ FGFR2 P21802 3/20 0.60
▸ JAK2 O60674 2/20 0.60
▸ ABL1 P00519 2/20 0.60
▸ INSR P06213 2/20 0.60
▸ FYN P06241 2/20 0.60
▸ YES1 P07947 2/20 0.60
▸ LYN P07948 2/20 0.60
▸ RET P07949 2/20 0.60
▸ MET P08581 2/20 0.60
▸ ROS1 P08922 2/20 0.60
▸ KIT P10721 2/20 0.60
▸ SRC P12931 2/20 0.60
▸ BRAF P15056 2/20 0.60
▸ PDGFRA P16234 2/20 0.60
▸ FLT1 P17948 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21862429 0.88 LCK (0.58) LCKFGFR3FGFR4ALKFGFR1
SCHEMBL27256691 0.87 LCK (0.62) LCKFGFR3FGFR4ALKFGFR1
SCHEMBL373634 0.84 HCK (0.56) LCKFGFR3FGFR4ALKFGFR1
SCHEMBL374708 0.84 HCK (0.58) LCKFGFR3FGFR4ALKFGFR1
SCHEMBL14660127 0.83 CD274 (0.57) LCKFGFR3FGFR4ALKFGFR1
SCHEMBL19848775 0.80 HCK (0.55) LCKFGFR3FGFR4ALKFGFR1
SCHEMBL22132803 0.76 FGFR3 (0.72) LCKFGFR3FGFR4ALKFGFR1
SCHEMBL18398033 0.76 FGFR3 (0.85) LCKFGFR3FGFR4ALKFGFR1
SCHEMBL19588439 0.76 FGFR3 (0.77) LCKFGFR3FGFR4ALKFGFR1
Infigratinib SCHEMBL374435 0.76 FGFR3 (1.00) LCKFGFR3FGFR4ALKFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3925622-A1 COMBINATION THERAPIES Novartis AG (CH) 2021-12-22 — — EP disclosed
EP-3659621-A1 COMBINATION THERAPIES FOR CANCER Novartis AG (CH) 2020-06-03 — — EP disclosed
EP-2902489-B9 FGFR3 FUSION GENE AND PHARMACEUTICAL DRUG TARGETING SAME CHUGAI PHARMACEUTICAL CO LTD (JP) 2018-02-07 — — EP disclosed
EP-2902489-B1 FGFR3 FUSION GENE AND PHARMACEUTICAL DRUG TARGETING SAME CHUGAI PHARMACEUTICAL CO LTD (JP) 2017-09-13 — — EP disclosed
Send feedback